PACTG P1061S: EVALUATION OF IMMUNOLOGIC MEMORY FOLLOWING PNEUMOCOCCAL, HEP B

PACTG P1061S：肺炎球菌、乙型肝炎后的免疫记忆评估

• 批准号: 7605120
• 负责人: MARK J ABZUG
• 金额: $ 2.31万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605120
• 关键词: Child; Childhood; Computer Retrieval of Information on Scientific Projects Database; Enrollment; Evaluation; Funding; Grant; Hepatitis B Vaccines; Highly Active Antiretroviral Therapy; Immunization; Immunologic Memory; Institution; Measles Vaccine; Mismatch Repair; Pneumococcal conjugate vaccine; Polyvalent pneumococcal vaccine; Population Study; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Vaccines; Visit; follow-up; immunogenicity

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. P1061S is a follow-up substudy of P1024 "Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Treated with Highly Active Antiretroviral Therapy" to evaluate the persistence of immunologic memory to pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPV), measles vaccine (MMR), and hepatitis B virus (HBV) vaccine in HIV-infected subjects on HAART who participated in, and completed, P1024. The study population is HIV-infected subjects who enrolled into P1024 between June 1, 2001 and March 31, 2002 and completed the initial two-year study period. This includes approximately 224 subjects, out of the original 263 subjects who participated in P1024. Approximately 149 subjects, out of the 224 subjects, are expected to enroll. Enrollment will be completed by January 18, 2006 to allow for the completion of study visits prior to the discontinuation of the PACTG.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 P1061 S是P1024“在接受高效抗逆转录病毒治疗的HIV感染儿童中评价肺炎球菌结合疫苗和常规儿科免疫接种的免疫原性”的后续子研究，旨在评价对肺炎球菌结合疫苗（PCV）和肺炎球菌多糖疫苗（PPV）、麻疹疫苗（MMR）、和B型肝炎病毒（HBV）疫苗在接受HAART的HIV感染受试者中的应用，这些受试者参加并完成了P1024。 研究人群为2001年6月1日至2002年3月31日期间入组P1024并完成最初两年研究期的HIV感染受试者。 这包括参与P1024的最初263例受试者中的约224例受试者。 预计224例受试者中约有149例受试者入组。 入组将于2006年1月18日完成，以便在PACTG停药前完成研究访视。